Viatris Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Viatris heeft een totaal eigen vermogen van $19.5B en een totale schuld van $17.1B, wat de schuld-eigenvermogensverhouding op 87.6% brengt. De totale activa en totale passiva bedragen respectievelijk $45.3B en $25.8B. De EBIT Viatris is $1.9B waardoor de rentedekking 3.4 is. Het heeft contanten en kortetermijnbeleggingen van $1.0B.

Belangrijke informatie

87.6%

Verhouding schuld/eigen vermogen

US$17.09b

Schuld

Rente dekkingsratio	3.4x
Contant	US$1.02b
Aandelen	US$19.52b
Totaal verplichtingen	US$25.81b
Totaal activa	US$45.33b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $11.8B ) VTRS } overtreffen de korte termijn passiva ( $7.7B ).

Langlopende schulden: De kortetermijnactiva van VTRS ( $11.8B ) dekken de langetermijnschulden ( $18.1B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 82.3% ) VTRS wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van VTRS is de afgelopen 5 jaar gedaald van 111.7% naar 87.6%.

Schuldendekking: De schuld van VTRS wordt niet goed gedekt door de operationele kasstroom ( 13.4% ).

Rentedekking: De rentebetalingen op de schuld van VTRS worden goed gedekt door EBIT ( 3.4 x dekking).

Viatris Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Viatris Inc. Declares Quarterly Dividend, Payable on December 13, 2024

Viatris Inc., Annual General Meeting, Dec 06, 2024

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Viatris Inc. Announces Positive Top-Line Results from Phase 3 Study of Effexor® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Viatris Launches (Pr) Viagra ODF in Canada

Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.12 announced

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024

Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS).

Director recently sold US$3.6m worth of stock

Director notifies of intention to sell stock

Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope

Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Viatris: Skeptics Proven Right Once Again

Chief Legal Officer recently sold US$928k worth of stock

First quarter dividend of US$0.12 announced

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023

Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.

Viatris Inc. Announces Changes to its Board

Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative

Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS).

Upcoming dividend of US$0.12 per share